Department of Clinical Biochemistry, Heartlands Hospital, Birmingham, UK.
Reprod Biol Endocrinol. 2012 Dec 17;10:113. doi: 10.1186/1477-7827-10-113.
Soluble LH/hCG receptor (sLHCGR) released from placental explants and transfected cells can be detected in sera from pregnant women. To determine whether sLHCGR has diagnostic potential, quantitative ELISAs were developed and tested to examine the correlation between pregnancy outcome and levels of serum sLHCGR and hCG-sLHCGR complex.
Anti-LHCGR poly- and monoclonal antibodies recognizing defined LHCGR epitopes, commerical anti-hCGbeta antibody, together with recombinant LHCGR and yoked hCGbeta-LHCGR standard calibrators were used to develop two ELISAs. These assays were employed to quantify serum sLHCGR and hCG-sLHCGR at first trimester human pregnancy.
Two ELISAs were developed and validated. Unlike any known biomarker, sLHCGR and hCG-sLHCGR are unique because Down's syndrome (DS), preeclampsia and preterm delivery are linked to both low (less than or equal to 5 pmol/mL), and high (equal to or greater than 170 pmol/mL) concentrations. At these cut-off values, serum hCG-sLHCGR together with PAPP-A detected additional DS pregnancies (21%) which were negative by free hCGbeta plus PAPP-A screening procedure. Therefore, sLHCGR/hCG-sLHCGR has an additive effect on the current primary biochemical screening of aneuploid pregnancies. More than 88% of pregnancies destined to end in fetal demise (stillbirth) exhibited very low serum hCG-sLHCGR(less than or equal to 5 pmol/mL) compared to controls (median 16.15 pmol/mL, n = 390). The frequency of high hCG-sLHCGR concentrations (equal to or greater than 170 pmol/mL) in pathological pregnancies was at least 3-6-fold higher than that of the control, suggesting possible modulation of the thyrotropic effect of hCG by sLHCGR.
Serum sLHCGR/hCG-sLHCGR together with PAPP-A, have significant potential as first trimester screening markers for predicting pathological outcomes in pregnancy.
从胎盘外植体和转染细胞中释放的可溶性 LH/hCG 受体 (sLHCGR) 可在孕妇血清中检测到。为了确定 sLHCGR 是否具有诊断潜力,开发了定量 ELISA 并进行了测试,以检查妊娠结局与血清 sLHCGR 和 hCG-sLHCGR 复合物水平之间的相关性。
使用抗 LHCGR 多克隆和单克隆抗体识别定义的 LHCGR 表位、商业抗 hCGβ 抗体,以及重组 LHCGR 和连接的 hCGβ-LHCGR 标准校准品,开发了两种 ELISA。这些测定法用于定量检测人妊娠早期的血清 sLHCGR 和 hCG-sLHCGR。
开发并验证了两种 ELISA。与任何已知的生物标志物不同,sLHCGR 和 hCG-sLHCGR 是独特的,因为唐氏综合征(DS)、先兆子痫和早产与低浓度(≤5pmol/mL)和高浓度(≥170pmol/mL)都有关联。在这些临界值下,血清 hCG-sLHCGR 与 PAPP-A 一起检测到额外的 DS 妊娠(21%),而游离 hCGβ+PAPP-A 筛查程序呈阴性。因此,sLHCGR/hCG-sLHCGR 对当前的非整倍体妊娠的主要生化筛查具有附加效应。与对照组(中位数 16.15pmol/mL,n=390)相比,超过 88%的注定以胎儿死亡(死产)结束的妊娠表现出非常低的血清 hCG-sLHCGR(≤5pmol/mL)。病理妊娠中高 hCG-sLHCGR 浓度(≥170pmol/mL)的频率至少是对照组的 3-6 倍,提示 sLHCGR 可能调节 hCG 的促甲状腺作用。
血清 sLHCGR/hCG-sLHCGR 与 PAPP-A 一起,具有作为预测妊娠病理结局的早期筛查标志物的显著潜力。